Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Matthew K. Fust sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.14, for a total transaction of $2,648,400.00. Following the completion of the sale, the director now directly owns […]
HC Wainwright reaffirmed their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. CRNX has been the topic of a number of other reports. JMP Securities upped their price target on shares of […]
Citigroup assumed coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note published on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $68.00 price objective on the stock. Several other equities research analysts also recently weighed in on CRNX. Oppenheimer increased their price target on Crinetics […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.01), Briefing.com reports. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 57.04%. The business’s revenue for […]
Profund Advisors LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.